Liquidia Corp (NASDAQ:LQDA) Chief Executive Officer Roger Jeffs moved to sell a block of company stock in mid-April, disposing of 54,177 shares across trades on April 10 and April 13, 2026, netting approximately $2.1 million. Per a Form 4 filed with the Securities and Exchange Commission, the shares were sold at prices between $38.37 and $40.1193, levels close to the stock's current trading price of $38.71. Over the past 12 months the stock has appreciated roughly 181%.
The same SEC filing notes that on April 10, Jeffs received 28,167 shares following the conversion of Performance Stock Units. The April 10 and April 13 disposals were executed under pre-existing trading programs - specifically, Rule 10b5-1 plans adopted on November 5, 2025 and December 15, 2023 respectively - according to the disclosure.
After these transactions, Jeffs' direct holdings in Liquidia total 1,137,599 shares, a figure that includes unvested restricted stock units. The filing also shows indirect ownership positions of 46,595 shares through the Roger A. Jeffs Living Trust and 1,495,234 shares held via Serendipity BioPharma LLC.
Separately, Liquidia Technologies released fourth-quarter 2025 results that highlighted a strong commercial performance for its Yutrepia treatment. The company reported $90.1 million in revenue for Yutrepia, a 74% increase from the prior quarter. Despite that top-line momentum, earnings per share missed expectations, a shortfall that prompted mixed reactions among investors.
Market analysts responded to the quarter and the product's launch dynamics with a range of upgraded targets and maintained ratings. H.C. Wainwright raised its price target to $55 and kept a Buy rating, citing the company's shift toward profitability. BTIG lifted its target to $50, pointing to the strong initial sales of Yutrepia. Raymond James reiterated a Strong Buy stance with a $47 target and compared Yutrepia's early launch performance to that of Tyvaso DPI. BofA Securities maintained a Buy rating and a $44 price target, noting Liquidia's competitive positioning in the prostacyclin treatment market.
Liquidia also provided forward-looking revenue guidance that exceeds $1 billion for 2027, a forecast that underscores management's confidence in the drug's commercial trajectory. In parallel, InvestingPro analysis cited in the filing suggests the shares may be undervalued at current levels, offering subscribers access to Fair Value estimates and additional analytical guidance.
These developments - insider sales executed under rule-compliant plans, robust product revenue, an earnings-per-share miss and a range of analyst reactions - create a complex backdrop for investors assessing Liquidia's near-term and medium-term prospects. The combined picture includes meaningful commercial progress for Yutrepia alongside continuing scrutiny over profitability metrics.